Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for MD 2
Most Correlated Studies
- CD34+ peripheral blood cells from MDS and AML patients treated with 5-azacytidine and entinostat
- Mesenchymal stromal cells of myelodysplastic syndrome (MDS) patients - RCMD and RAEB subtypes
- Breast adenocarcinoma MD-MBA-231 cells with shRNA knockdown of both WDR77 and PRMT5
- Common myeloid and granulocyte-macrophage progenitors from a myelodysplastic syndrome (MDS) model
- Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Codelink]
Most Relevant Literature
- Folic acid derived-P5779 mimetics regulate DAMP-mediated inflammation through disruption of HMGB1:TL…
- Ginsenoside Rh2 Alleviates LPS-Induced Inflammatory Responses by Binding to TLR4/MD-2 and Blocking T…
- Biomarkers of treatment success in fully sensitive pulmonary tuberculosis patients: a multicenter lo…
- Signatures of positive selection in LY96 gene in vertebrates.
- Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2.
Most Relevant Clinical Trials
- Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts…
- G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Under…
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,…
- Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
